BioSpace News Archive

SphereShield integration with BlackBerry UEM enables secure access to Skype for Business on mobile devices

Swisslog Healthcare addresses medication safety and access challenges in long-term care settings through in-facility dispensing technology

Bloom, targeting rare epileptic syndromes with orally-delivered pharmaceutical compositions of specific combined strains of naturally-occurring microbes, today announced the initiation of a microbiome sample collection study titled: Effects of the Ketogenic Diet on the Gut Microbiota.

MilliporeSigma today officially opened a state-of-the-art M Lab™ Collaboration Center in Brazil, serving the Latin America region.

Innovatus Capital Partners, LLC (“Innovatus” or the “Firm”), an independent adviser and portfolio management firm with approximately $1.6 billion in assets under management, today announced that it has entered into a financing agreement with Personal Genome Diagnostics, Inc.

CCRM (Colorado Center for Reproductive Medicine), a global pioneer in fertility science, research and treatment, today announced the addition of Carter Owen, M.D. to its team of award-winning fertility specialists.

Patients suffering from chronic obstructive pulmonary disease (COPD) with chronic respiratory failure (CRF) using home non-invasive ventilation (NIV) live longer, are less likely to be admitted to a hospital and cost Medicare significantly less than patients using other devices.

miR Scientific, LLC formerly known as miR Diagnostics (miR or the Company), a precision molecular bioscience company, today announces that Martin Tenniswood, Ph.D., Chief Scientific Officer presented at the 2018 World Urological Oncology Federation Conference to be held in Seoul, Korea on October 4, 2018 at 12:10PM Korea Time.

Veterans and their families gathered at their neighborhood Home Depot for Wounded Warrior Project® (WWP) do-it-yourself workshop.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that at the special meeting of stockholders, held September 28, 2018